ADMA · Adma Biologics, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $121.5M | First Half 2026 | — |
|
|
|||
| Adjusted Net Income non-GAAP | $79.6M | First Half 2026 | — |
|
|
|||
| ASCENIV Revenue | $102.92M | FY2026 Q2 | +23.5% |
|
|
|||
| Gross margin | 70% | Six months ended June 30, 2026 | — |
| Share repurchases as percent of outstanding shares | 5.3% | Year-to-date through June 30, 2026 | — |
| Shares converted to treasury stock | 3.7% | through March 31, 2026 | — |
| Operating cash flow | $40M | 4Q 2025 | — |
| Total cash | $88M | Year-End 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ADMA
this stock
Adma Biologics, Inc.
|
$2.09B | -48.8% | +43.9% | 13.3 | 10.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +2.9% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$63.63B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ADMA | -5.1% | +10.4% | -40.9% | +10.4% | -48.8% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -5.6% | +7.4% | -54.4% | +7.4% | -61.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.